Predicting Recurrence in Early Melanoma
Study identifies tumor features beyond staging that predict recurrence risk in early disease
-
By
-
Andrea Surnit
-
April 1, 2026
-
Clinical Scorecard: Predicting Recurrence in Early Melanoma
At a Glance
| Category | Detail |
|---|
| Condition | Early Melanoma (Stage I and II) |
| Key Mechanisms | Ulceration, tumor thickness, anatomic site, neurotropism, lymphovascular invasion, presence of mitoses |
| Target Population | Patients with stage IA to IIC melanoma diagnosed between 2010 and 2017 |
| Care Setting | Single-center cohort study |
Key Highlights
- 16% of patients experienced recurrence over a median follow-up of 7 years
- Recurrence rates increased from 4% in stage IA to 37% in stage IIB
- Distant recurrence accounted for 48% of cases
- Ulceration and tumor thickness were significant predictors of recurrence
- Melanomas on the scalp or neck had higher recurrence rates
Guideline-Based Recommendations
Diagnosis
- Consider additional pathologic features such as neurotropism and lymphovascular invasion in recurrence risk assessment
Management
- Incorporate identified risk factors into surveillance strategies for melanoma recurrence
Monitoring & Follow-up
- Utilize Kaplan-Meier analyses to evaluate recurrence-free survival based on tumor location and features
Risks
- Higher recurrence associated with older age, male sex, and higher comorbidity burden
Patient & Prescribing Data
1,092 patients with stage IA to IIC melanoma
Recurrence risk varies significantly with tumor characteristics and patient demographics
Clinical Best Practices
- Evaluate tumor thickness and ulceration during initial assessment
- Consider anatomic site when planning follow-up and surveillance
- Incorporate comprehensive pathologic features into staging and monitoring
References
